News

The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active celiac disease subjects adhering to

BioFocus DPI will use the high purity, clinical grade human motor neurons to perform assay development and screening for amyotrophic lateral sclerosis (ALS or ‘Lou Gehrig’s disease’) drug

Daiichi Sankyo will purchase 100% of the stock and make a one-time payment of E150 million for the company. Closure of the transaction is subject to clearance under

Steve Guillen, president of MedX Health, said: “We have said publicly that it is our intention to accelerate the development of this new product, aimed at the large

The study, which took place at two sites, consisted of 38 pediatric patients ages 2-12. The mean age was six years. Patients were randomized into two groups: one

Under the agreement, BD (Becton, Dickinson and Company) will fund a research program at Accelr8 through September 30, 2009. The research program includes mutually agreed milestones to support

Quidel will now have access to a new molecular product, particularly suited for the acute care laboratory market. The ProFlu+ test provides a complementary product offering to the

The Southwest Oncology Group (SWOG), a cancer network sponsored by the National Cancer Institute (NCI), is evaluating IMC-A12, ImClone’s fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal

Ferralet 90 contains 90mg of carbonyl iron as well as essential vitamins and minerals to help patients replenish iron stores in an effective, safe and tolerable manner. Ferralet